<DOC>
<DOCNO>..Data\515\086</DOCNO>
<FROM>wqtw93r86vzs4y3299zr29ufqo3@info.wojxfd.com</FROM>
<TO>6kjhy17@a9hj.edu.cn</TO>
<SUBJECT>British Journal of Cancer - Table of Contents alert  Volume 94 Issue 8</SUBJECT>
<TEXT>
<!--
	
	

	.nav, 3.z94:link, 3.z94:visited {font-family: Verdana, Arial, Helvetica, sans-serif; font-size: 12px; color: 		

	#000000; text-decoration: none;}
	3.z94:hover {color: #663399;}

	.searchbar, 3.z848kqy95:link, 3.z848kqy95:visited {font-family: Verdana, Arial, Helvetica, sans-serif; font-size: 

	10px; color: #330066; font-weight: bold; text-decoration: none;}
	3.z848kqy95:hover {color: #000000;}

	.toollink, 3.s3m1e0yw:link, 3.s3m1e0yw:visited {font-family: Verdana, Arial, Helvetica, sans-serif; font-size: 		

10px; color: #999999; text-decoration: none;}
	3.s3m1e0yw:hover {color: #663399;}

-->
















	
	
	
	
		
		
		
		
		
		
		

	
	
		
	



	
	
	
	
	


		
		
		SEARCH
		
		
		








		
		
		
		
		
		
		
		
		
		
		
		
		 advanced  search
		
		 help
		
		 site index
	
		
		
	
	
	
	






 



	
   	
    		
			
			New Issue - Table of Contents
			
		
	
	


	
		
	


	
		
		
			
				


				
				


				
				
					Current issue
				
					Online sample 				issues
					
					Order sample copy

				
					Subscribe

	

				
					Access the journal archive

		
				
					
				Submitting to BJC

				
					
				BJC home page
				
		
				
			
			
				
				
				
			
		
		
			
				 
			
		
	

	
		
	




 



	 
	


	 
		
		 
		 
		

New mailing address for British Journal of Cancer (BJC)!

Use the following new address to submit your manuscript to BJC:
British Journal of Cancer
University College London
Department of Oncology
91 Riding House Street
London WlW 7BS
UK

Don't forget to visit the journal's homepage for a variety of free featured articles or to request a sample copy.
		
		
		
		 
		
		
	
	


 

 







24 April 2006, Volume 94, Number 8












Review

back to top








Epigenetics as a mechanism driving polygenic clinical drug resistance
R M Glasspool, J M Teodoridis  R Brown



AbstractFull Article



1087







Clinical Studies

back to top








Anxiety and depression after prostate cancer diagnosis and treatment: 5-year follow-up
I J Korfage, M-L Essink-Bot, A C J W Janssens, F H Schr?der  H J de Koning



AbstractFull Article



1093




Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pN2 non-small-cell lung cancer: 5-year follow-up of a phase II study
D C Betticher, S-F Hsu Schmitz, M T?tsch, E Hansen, C Joss, C von Briel, R A Schmid, M Pless, J Habicht, A D Roth, A Spiliopoulos, R Stahel, W Weder, R Stupp, F Egli, M Furrer, H Honegger, M Wernli, T Cerny  H-B Ris for the Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland



AbstractFull Article



1099




Gastrazole (JB95008), a novel CCK2/gastrin receptor antagonist, in the treatment of advanced pancreatic cancer: results from two randomised controlled trials
I Chau, D Cunningham, C Russell, A R Norman, T Kurzawinski, P Harper, P Harrison, G Middleton, F Daniels, T Hickish, J Prendeville, P J Ross, B Theis, R Hull, M Walker, N Shankley, B Kalindjian, G Murray, A Gillbanks  J Black



AbstractFull Article



1107




General practice vs surgical-based follow-up for patients with colon cancer: randomised controlled trial
D A Wattchow, D P Weller, A Esterman, L S Pilotto, K McGorm, Z Hammett, C Platell  C Silagy



AbstractFull Article



1116




Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial
J Cassidy, J-Y Douillard, C Twelves, J J McKendrick, W Scheithauer, I Bustov¨¢, P G Johnston, K Lesniewski-Kmak, S Jelic, G Fountzilas, F Coxon, E D¨ªaz-Rubio, T S Maughan, A Malzyner, O Bertetto, A Beham, A Figer, P Dufour, K K Patel, W Cowell  L P Garrison



AbstractFull Article



1122




Phase I/II study of S-1 combined with irinotecan for metastatic advanced gastric cancer
M Inokuchi, T Yamashita, H Yamada, K Kojima, W Ichikawa, Z Nihei, T Kawano  K Sugihara



AbstractFull Article



1130




Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer
C A Townsley, P Major, L L Siu, J Dancey, E Chen, G R Pond, T Nicklee, J Ho, D Hedley, M Tsao, M J Moore  A M Oza



AbstractFull Article



1136







Translational Therapeutics

back to top








HER2 expression as a potential marker for response to therapy targeted to the EGFR
D R Emlet, R Schwartz, K A Brown, A A Pollice, C A Smith  S E Shackney



AbstractFull Article



1144




COX-2-mediated stimulation of the lymphangiogenic factor VEGF-C in human breast cancer
A V Timoshenko, C Chakraborty, G F Wagner  P K Lala



AbstractFull Article



1154







Molecular Diagnostics

back to top








Detection of occult carcinomatous diffusion in lymph nodes from head and neck squamous cell carcinoma using real-time RT?PCR detection of cytokeratin 19 mRNA
L Tao, M Lef¨¨vre, S Ricci, P Saintigny, P Callard, S P¨¦ri¨¦, R Lacave, J-F Bernaudin  J Lacau St Guily



AbstractFull Article



1164




A minimally invasive immunocytochemical approach to early detection of oral squamous cell carcinoma and dysplasia
I S Scott, E Odell, P Chatrath, L S Morris, R J Davies, S L Vowler, R A Laskey  N Coleman



AbstractFull Article



1170




Is nonangiogenesis a novel pathway for cancer progression? A study using 3-dimensional tumour reconstructions
O Adighibe, K Micklem, L Campo, M Ferguson, A Harris, R Pozos, K Gatter  F Pezzella



AbstractFull Article



1176




Co expression of SCF and KIT in gastrointestinal stromal tumours (GISTs) suggests an autocrine/paracrine mechanism
N Th¨¦ou-Anton, S Tabone, D Brouty-Boy¨¦, R Saffroy, L Ronnstrand, A Lemoine  J-F Emile



AbstractFull Article



1180







Genetics and Genomics

back to top








Expression of ADAMTS-8, a secreted protease with antiangiogenic properties, is downregulated in brain tumours
J R Dunn, J E Reed, D G du Plessis, E J Shaw, P Reeves, A L Gee, P Warnke  C Walker



AbstractFull Article



1186




Radiosensitivity in breast cancer assessed by the Comet and micronucleus assays
C S Djuzenova, B M¨¹hl, M Fehn, U Oppitz, B M¨¹ller  M Flentje



AbstractFull Article



1194




Net1 and Myeov: computationally identified mediators of gastric cancer
J Leyden, D Murray, A Moss, M Arumuguma, E Doyle, G McEntee, C O'Keane, P Doran  P MacMathuna



AbstractFull Article



1204







Letters to the Editor

back to top








HER2 (ErbB2) receptors, a potential therapeutic target in squamous cell carcinoma of oesophagus
A N Khan, W Yang, A M Seifalian  M C Winslet



AbstractFull Article



1213




Reply: Her2 (ErbB2) receptors, a potential therapeutic target in squamous cell carcinoma of oesophagus?
J-P Metges, L Gibault, V Conan-Charlet, P Lozac'H, M Robaszkiewicz, C Bessaguet, N Lagarde  A Volant



AbstractFull Article



1214






























 


 
  
  
    

  
  
    

  
  
    

  
  
    
      
        
        
          

  
  

    
      
You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your wojxfd.com account at: www.nb6yyv.com/nams/svc/myaccount
      (You will need to log in to be recognised as a wojxfd.com registrant)
      For further technical assistance, please contact our registration department
      
      For print subscription enquiries, please contact our subscription department
      
      For other enquiries, please contact our customer feedback department

	Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA
      Nature Publishing Group's worldwide offices: London - Paris -
      Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco -
      Washington - New York - Boston

  
  
    

  
  
    

  
  
    

  
  

    
       2006
      Cancer Research UK

  

 












	
	
	
	
		
		
		
		
		
		
		

	
	
		
	



	
	
	
	
	


		
		
		SEARCH
		
		
		








		
		
		
		
		
		
		
		
		
		
		
		
		 advanced  search
		
		 help
		
		 site index
	
		
		
	
	
	
	






 



	
   	
    		
			
			New Issue - Table of Contents
			
		
	
	


	
		
	


	
		
		
			
				


				
				


				
				
					Current issue
				
					Online sample 				issues
					
					Order sample copy

				
					Subscribe

	

				
					Access the journal archive

		
				
					
				Submitting to BJC

				
					
				BJC home page
				
		
				
			
			
				
				
				
			
		
		
			
				 
			
		
	

	
		
	




 



	 
	


	 
		
		 
		 
		

New mailing address for British Journal of Cancer (BJC)!

Use the following new address to submit your manuscript to BJC:
British Journal of Cancer
University College London
Department of Oncology
91 Riding House Street
London WlW 7BS
UK

Don't forget to visit the journal's homepage for a variety of free featured articles or to request a sample copy.
		
		
		
		 
		
		
	
	


 

 







24 April 2006, Volume 94, Number 8












Review

back to top








Epigenetics as a mechanism driving polygenic clinical drug resistance
R M Glasspool, J M Teodoridis  R Brown



AbstractFull Article



1087







Clinical Studies

back to top








Anxiety and depression after prostate cancer diagnosis and treatment: 5-year follow-up
I J Korfage, M-L Essink-Bot, A C J W Janssens, F H Schr?der  H J de Koning



AbstractFull Article



1093




Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pN2 non-small-cell lung cancer: 5-year follow-up of a phase II study
D C Betticher, S-F Hsu Schmitz, M T?tsch, E Hansen, C Joss, C von Briel, R A Schmid, M Pless, J Habicht, A D Roth, A Spiliopoulos, R Stahel, W Weder, R Stupp, F Egli, M Furrer, H Honegger, M Wernli, T Cerny  H-B Ris for the Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland



AbstractFull Article



1099




Gastrazole (JB95008), a novel CCK2/gastrin receptor antagonist, in the treatment of advanced pancreatic cancer: results from two randomised controlled trials
I Chau, D Cunningham, C Russell, A R Norman, T Kurzawinski, P Harper, P Harrison, G Middleton, F Daniels, T Hickish, J Prendeville, P J Ross, B Theis, R Hull, M Walker, N Shankley, B Kalindjian, G Murray, A Gillbanks  J Black



AbstractFull Article



1107




General practice vs surgical-based follow-up for patients with colon cancer: randomised controlled trial
D A Wattchow, D P Weller, A Esterman, L S Pilotto, K McGorm, Z Hammett, C Platell  C Silagy



AbstractFull Article



1116




Pharmacoeconomic analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial
J Cassidy, J-Y Douillard, C Twelves, J J McKendrick, W Scheithauer, I Bustov¨¢, P G Johnston, K Lesniewski-Kmak, S Jelic, G Fountzilas, F Coxon, E D¨ªaz-Rubio, T S Maughan, A Malzyner, O Bertetto, A Beham, A Figer, P Dufour, K K Patel, W Cowell  L P Garrison



AbstractFull Article



1122




Phase I/II study of S-1 combined with irinotecan for metastatic advanced gastric cancer
M Inokuchi, T Yamashita, H Yamada, K Kojima, W Ichikawa, Z Nihei, T Kawano  K Sugihara



AbstractFull Article



1130




Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer
C A Townsley, P Major, L L Siu, J Dancey, E Chen, G R Pond, T Nicklee, J Ho, D Hedley, M Tsao, M J Moore  A M Oza



AbstractFull Article



1136







Translational Therapeutics

back to top








HER2 expression as a potential marker for response to therapy targeted to the EGFR
D R Emlet, R Schwartz, K A Brown, A A Pollice, C A Smith  S E Shackney



AbstractFull Article



1144




COX-2-mediated stimulation of the lymphangiogenic factor VEGF-C in human breast cancer
A V Timoshenko, C Chakraborty, G F Wagner  P K Lala



AbstractFull Article



1154







Molecular Diagnostics

back to top








Detection of occult carcinomatous diffusion in lymph nodes from head and neck squamous cell carcinoma using real-time RT?PCR detection of cytokeratin 19 mRNA
L Tao, M Lef¨¨vre, S Ricci, P Saintigny, P Callard, S P¨¦ri¨¦, R Lacave, J-F Bernaudin  J Lacau St Guily



AbstractFull Article



1164




A minimally invasive immunocytochemical approach to early detection of oral squamous cell carcinoma and dysplasia
I S Scott, E Odell, P Chatrath, L S Morris, R J Davies, S L Vowler, R A Laskey  N Coleman



AbstractFull Article



1170




Is nonangiogenesis a novel pathway for cancer progression? A study using 3-dimensional tumour reconstructions
O Adighibe, K Micklem, L Campo, M Ferguson, A Harris, R Pozos, K Gatter  F Pezzella



AbstractFull Article



1176




Co expression of SCF and KIT in gastrointestinal stromal tumours (GISTs) suggests an autocrine/paracrine mechanism
N Th¨¦ou-Anton, S Tabone, D Brouty-Boy¨¦, R Saffroy, L Ronnstrand, A Lemoine  J-F Emile



AbstractFull Article



1180







Genetics and Genomics

back to top








Expression of ADAMTS-8, a secreted protease with antiangiogenic properties, is downregulated in brain tumours
J R Dunn, J E Reed, D G du Plessis, E J Shaw, P Reeves, A L Gee, P Warnke  C Walker



AbstractFull Article



1186




Radiosensitivity in breast cancer assessed by the Comet and micronucleus assays
C S Djuzenova, B M¨¹hl, M Fehn, U Oppitz, B M¨¹ller  M Flentje



AbstractFull Article



1194




Net1 and Myeov: computationally identified mediators of gastric cancer
J Leyden, D Murray, A Moss, M Arumuguma, E Doyle, G McEntee, C O'Keane, P Doran  P MacMathuna



AbstractFull Article



1204







Letters to the Editor

back to top








HER2 (ErbB2) receptors, a potential therapeutic target in squamous cell carcinoma of oesophagus
A N Khan, W Yang, A M Seifalian  M C Winslet



AbstractFull Article



1213




Reply: Her2 (ErbB2) receptors, a potential therapeutic target in squamous cell carcinoma of oesophagus?
J-P Metges, L Gibault, V Conan-Charlet, P Lozac'H, M Robaszkiewicz, C Bessaguet, N Lagarde  A Volant



AbstractFull Article



1214






























 


 
  
  
    

  
  
    

  
  
    

  
  
    
      
        
        
          

  
  

    
      
You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your wojxfd.com account at: www.nb6yyv.com/nams/svc/myaccount
      (You will need to log in to be recognised as a wojxfd.com registrant)
      For further technical assistance, please contact our registration department
      
      For print subscription enquiries, please contact our subscription department
      
      For other enquiries, please contact our customer feedback department

	Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA
      Nature Publishing Group's worldwide offices: London - Paris -
      Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco -
      Washington - New York - Boston

  
  
    

  
  
    

  
  
    

  
  

    
       2006
      Cancer Research UK
</TEXT>
</DOC>

